Akebia Therapeutics Inc. buy BTIG Research
Start price
29.11.23
/
50%
€0.92
Target price
29.11.24
€3.64
Performance (%)
122.78%
End price
30.11.24
€2.05
Summary
This prediction ended on 30.11.24 with a price of €2.05. With a performance of 122.78% the BUY prediction by BTIG_Research was a big success. BTIG_Research has a follow-up prediction for Akebia Therapeutics Inc. where he still thinks Akebia Therapeutics Inc. is a Buy. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Akebia Therapeutics Inc. | -1.885% | -1.885% | -49.291% |
| iShares Core DAX® | -1.764% | 2.259% | 15.847% |
| iShares Nasdaq 100 | -1.632% | -0.193% | 4.686% |
| iShares Nikkei 225® | -2.451% | 4.086% | 16.083% |
| iShares S&P 500 | -2.252% | -0.151% | 1.636% |
Comments by BTIG_Research for this prediction
In the thread Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
In the thread Trading Akebia Therapeutics Inc.
Die von BTIG_Research gewählte maximale Laufzeit wurde überschritten
Current prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.93
29.10.25
29.10.25
€4.29
29.10.26
29.10.26
-40.09%
07:38
07:38
Stopped prediction by BTIG_Research for Akebia Therapeutics Inc.
Akebia Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.27
02.12.25
02.12.25
€4.31
02.12.26
02.12.26
-9.34%
07:38
07:38